To date, eight allosteric inhibitors of SHP2, including JAB-3068 [1], JAB-3312 [19], TNO155 [20], RMC-4630 [21], BBP-398 [22], ERAS-601 [23], RLY-1971 [24], and SH3809 [2], have entered clinical trials for cancer therapy. Here, PTPN11 is linked to cancer.